Neuroloxía

2023

1. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease

   Parkinsonism and Related Disorders, Vol. 110

2. A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

   Multiple Sclerosis Journal

3. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

   Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

4. Actualización en esclerosis múltiple: manifestaciones clínicas, formas evolutivas y estudios paraclínicos

   Medicine: Programa de Formación Médica Continuada Acreditado, Serie 13, Núm. 78, pp. 4621-4627

5. Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study

   European Archives of Psychiatry and Clinical Neuroscience

6. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.

   Multiple Sclerosis and Related Disorders, Vol. 75

7. Alpha-Synuclein in Peripheral Tissues as a Possible Marker for Neurological Diseases and Other Medical Conditions

   Biomolecules, Vol. 13, Núm. 8

8. Analysis of endothelial gene polymorphisms in Spanish patients with vascular dementia and Alzheimer´s disease

   Scientific Reports, Vol. 13, Núm. 1

9. Assessment of Upper Extremity Function in Multiple Sclerosis: Feasibility of a Digital Pinching Test

   JMIR Formative Research, Vol. 7

10. Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel

    Neurology and Therapy, Vol. 12, Núm. 2, pp. 427-439

11. Association between Mild Behavioral Impairment trajectories and AD biomarkers in adults with Mild Cognitive Impairment. Results from the CompAS study

    Alzheimer's & Dementia, Vol. 19, Núm. S14

12. Association between periodontitis and peripheral markers of innate immunity activation and inflammation

    Journal of Periodontology, Vol. 94, Núm. 1, pp. 11-19

13. Association of Early Progression Independent of Relapse Activity with Long-term Disability after a First Demyelinating Event in Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 2, pp. 151-160

14. Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event

    Neurology, Vol. 101, Núm. 13, pp. E1280-E1292

15. Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients

    European Journal of Neurology

16. Association of periodontitis with cognitive decline and its progression: Contribution of blood-based biomarkers of Alzheimer's disease to this relationship

    Journal of Clinical Periodontology, Vol. 50, Núm. 11, pp. 1444-1454

17. Astrocytic insulin receptor controls circadian behavior via dopamine signaling in a sexually dimorphic manner

    Nature Communications, Vol. 14, Núm. 1

18. Best practices in phase III clinical trials on DMTs for multiple sclerosis: A systematic analysis and appraisal of published trials

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 95, Núm. 4, pp. 333-341

19. Beyond hyperglycemia: glycaemic variability as a prognostic factor after acute ischemic stroke

    Neurologia, Vol. 38, Núm. 3, pp. 150-158

20. Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology

    Alzheimer's and Dementia, Vol. 19, Núm. 9, pp. 3815-3825